Tennessee Headlines

DelveInsight’s Pompe Disease market report provides an in-depth understanding of the disease, historical and projected epidemiology, as well as Pompe Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report also covers current treatment practices/algorithms, market drivers, market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.

Some of the Crucial Highlights from the Pompe Disease Market Report

• According to Delveinsight, there were 12,790 Pompe Disease cases reported in 2020.

• In 2020, Germany had the highest prevalence of Pompe Disease in the EU5 countries, with 821 cases, followed by France, which had a prevalence of 689 cases. Spain, on the other hand, had the lowest prevalence population in 2020, with 505 cases.

• According to Delveinsight, the number of cases of Infantile-onset Pompe Disease and Late-onset Pompe Disease in Japan in 2020 was 151 and 926, respectively, and is expected to rise by 2030.

• Avalglucosidase alfa (Sanofi), AT-GAA (Amicus Therapeutics), ACTUS-101 (Actus Therapeutics), VAL-1221 (Valerion Therapeutics), AT845 (Audentes Therapeutics), SPK-3006 (Roche)are some of the most anticipated emerging therapies in the Pompe Disease market.

• Leading pharmaceutical companies such as Sanofi, Amicus Therapeutics, Actus Therapeutics, Valerion Therapeutics, Audentes Therapeutics, Roche, among others are working proactively in the Pompe Disease market.

Want to know more? Request sample @ Pompe Disease Market Size

The Pompe Disease report provides current treatment methods, developing medications, individual therapy market share, and present and expected market sizes for Pompe Disease from 2018 to 2030, segmented by seven major markets.

Pompe Disease: Overview

Pompe disease (PD), also known as glycogen storage disease type II (GSDII) or “acid maltase deficiency,” is characterised by a lack of acid alpha-glucosidase (GAA), a lysosomal enzyme responsible for the breaking of glycogen -1, 4- and -1, 6-glycosidic linkages to glucose. Pompe Disease manifests itself at various ages and with varying degrees of severity. The nature of the mutation and the degree of residual enzyme activity generally correlate well with the severity of the clinical presentations, tissue involvement, and age of onset.

Pompe Disease Epidemiology Segmentation

• Pompe Disease Total Live Birth Cases

• Pompe Disease Total Adult Prevalent Cases

• Pompe Disease Total Prevalent Cases

• Pompe Disease Prevalence by Onset Types

• Infantile Onset Pompe Disease Incidence based on Clinical Phenotype

Pompe Disease Treatment Landscape

The treatment for Pompe Disease is symptomatic, supportive, and disease-specific. Individuals with Pompe Disease are treated by a team of experts who are familiar with the condition (such as cardiologists, neurologists, and respiratory therapists) and can provide supportive and symptomatic care.

Pompe Disease Market

Companies all over the world such as Sanofi, Amicus Therapeutics, Actus Therapeutics, Valerion Therapeutics, Audentes Therapeutics, Roche, and others have been working hard for years to develop novel treatment therapies in the Pompe Disease market.

The introduction of pipeline therapies such as Avalglucosidase alfa (Sanofi), AT-GAA (Amicus Therapeutics), ACTUS-101 (Actus Therapeutics), VAL-1221 (Valerion Therapeutics), AT845 (Audentes Therapeutics), SPK-3006 (Roche) and others will boost the Pompe Disease market in the forecast period 2021-30 in the 7MM.

Learn more about pompe disease @ Pompe Disease Treatment Approaches

Pompe Disease Pipeline Therapies and Key Companies

• Avalglucosidase alfa: Sanofi

• AT-GAA: Amicus Therapeutics

• ACTUS-101: Actus Therapeutics

• VAL-1221: Valerion Therapeutics

• AT845: Audentes Therapeutics

• SPK-3006: Roche

Pompe Disease Market Drivers

• Upcoming therapies

• Side effects of existing therapies

• Improved disease understanding

Pompe Disease Marker Barriers

• Diagnostic delays

• Complexity of production procedures

• High cost of therapies

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Pompe Disease Key Companies: Sanofi, Amicus Therapeutics, Actus Therapeutics, Valerion Therapeutics, Audentes Therapeutics, Roche, among others. 

Pompe Disease Key Pipeline Therapies: Avalglucosidase alfa (Sanofi), AT-GAA (Amicus Therapeutics), ACTUS-101 (Actus Therapeutics), VAL-1221 (Valerion Therapeutics), AT845 (Audentes Therapeutics), SPK-3006 (Roche), and others.

Pompe Market Segmentation: By Geography, By Pompe Disease therapies

Analysis: Comparative and conjoint analysis of Pompe Disease emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Celiac Disease Market

Get comprehensive historical and forecast analysis of Celiac Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Takeda/Cour Pharmaceuticals, Precigen ActoBio, Falk Pharma and Zedira, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/